Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson, Niki Arya, Johan Bodegård, Niklas Hammar, Peter Fenici. Circulation 2017
Times Cited: 383
Times Cited: 383
Karin Rådholm, Gemma Figtree, Vlado Perkovic, Scott D Solomon, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Terrance D Barrett, Wayne Shaw, Mehul Desai, David R Matthews, Bruce Neal. Circulation 2018
Times Cited: 170
Times Cited: 170
List of shared articles
Times cited
A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe.
S Seidu, X Cos, S Brunton, S B Harris, S P O Jansson, M Mata-Cases, A M J Neijens, P Topsever, K Khunti. Prim Care Diabetes 2021
S Seidu, X Cos, S Brunton, S B Harris, S P O Jansson, M Mata-Cases, A M J Neijens, P Topsever, K Khunti. Prim Care Diabetes 2021
Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents.
Yen-Wen Chen, Jennifer Voelker, Ozgur Tunceli, Christopher D Pericone, Brahim Bookhart, Michael Durkin. J Med Econ 2020
Yen-Wen Chen, Jennifer Voelker, Ozgur Tunceli, Christopher D Pericone, Brahim Bookhart, Michael Durkin. J Med Econ 2020
Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.
Vincent C Woo. Can J Diabetes 2020
Vincent C Woo. Can J Diabetes 2020
Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
Dalal Y Al-Bazz, John Ph Wilding. Future Cardiol 2020
Dalal Y Al-Bazz, John Ph Wilding. Future Cardiol 2020
Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Javed Butler, Yehuda Handelsman, George Bakris, Subodh Verma. Eur J Heart Fail 2020
Javed Butler, Yehuda Handelsman, George Bakris, Subodh Verma. Eur J Heart Fail 2020
Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2.
Srikanth Yandrapalli, Aaqib Malik, Adam Horblitt, Gayatri Pemmasani, Wilbert S Aronow, William H Frishman. Cardiol Rev 2020
Srikanth Yandrapalli, Aaqib Malik, Adam Horblitt, Gayatri Pemmasani, Wilbert S Aronow, William H Frishman. Cardiol Rev 2020
Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini. Diabetes Obes Metab 2020
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini. Diabetes Obes Metab 2020
Reappraisal on pharmacological and mechanical treatments of heart failure.
Bo Liang, Yu-Xiu Zhao, Xiao-Xiao Zhang, Hui-Ling Liao, Ning Gu. Cardiovasc Diabetol 2020
Bo Liang, Yu-Xiu Zhao, Xiao-Xiao Zhang, Hui-Ling Liao, Ning Gu. Cardiovasc Diabetol 2020
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri. Clin Drug Investig 2020
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri. Clin Drug Investig 2020
The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.
Hung-Yi Chen, Jing-Yang Huang, Wun-Zhih Siao, Gwo-Ping Jong. Cardiovasc Diabetol 2020
Hung-Yi Chen, Jing-Yang Huang, Wun-Zhih Siao, Gwo-Ping Jong. Cardiovasc Diabetol 2020
2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu,[...]. J Chin Med Assoc 2020
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu,[...]. J Chin Med Assoc 2020
Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence.
Phil McEwan, Hayley Bennett, Kamlesh Khunti, John Wilding, Christopher Edmonds, Marcus Thuresson, Eric Wittbrodt, Peter Fenici, Mikhail Kosiborod. Diabetes Obes Metab 2020
Phil McEwan, Hayley Bennett, Kamlesh Khunti, John Wilding, Christopher Edmonds, Marcus Thuresson, Eric Wittbrodt, Peter Fenici, Mikhail Kosiborod. Diabetes Obes Metab 2020
Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
André J Scheen. Nat Rev Endocrinol 2020
André J Scheen. Nat Rev Endocrinol 2020
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure.
Mieczysław Dutka, Rafał Bobiński, Izabela Ulman-Włodarz, Maciej Hajduga, Jan Bujok, Celina Pająk, Michał Ćwiertnia. Heart Fail Rev 2020
Mieczysław Dutka, Rafał Bobiński, Izabela Ulman-Włodarz, Maciej Hajduga, Jan Bujok, Celina Pająk, Michał Ćwiertnia. Heart Fail Rev 2020